Médecine

Paramédical

Autres domaines


Suscribirse

The role of Interleukin 6 inhibitors in therapy of severe COVID-19 - 28/10/20

Doi : 10.1016/j.biopha.2020.110698 
E. Nasonov a, b, c, d , M. Samsonov e,
a V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 
b I.M. Sechenov First Moscow State Medical University, MOH, Moscow, Russia 
c Kashirskoye roadway, 34А, 1115522, Moscow, Russia 
d Trubetskaya str, 8, bdg. 2, 2119991, Moscow, Russia 
e RPharm JSC, Leninsky prospect 111, 11942, Moscow, Russia 

Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Graphical abstract

The role of interleukin 6 inhibitors in therapy of severe COVID-19 Nassonov E, Samsonov M.

RM, Resident macrophages; INF, interferons; NK, natural killers; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor, TNFα, tumor necrosis factor alpha; IP-10, interferon (IFN)γ-induced protein 10; MIP1α, macrophage inflammatory protein; CCL2, CCL7, CXCL9, CXCL10, chemokines.




El texto completo de este artículo está disponible en PDF.

Highlights

Hyperimmune activation plays key role in severe COVID-19.
IL-6 increase associated with poor prognosis and progression.
IL-6 inhibition may improve patient’s conditions.
Treat to target strategy may be applied in COVID-19.

El texto completo de este artículo está disponible en PDF.

Abstract

Cytokine storm syndrome (CSS) is a severe complication of inflammatory immune diseases or treatment of malignancies; it may also appear during the progression of COVID-19. CSS is caused by dysregulation of the synthesis of cytokines, including pro-inflammatory, regulatory, and anti-inflammatory cytokines and chemokines, leading to pathologic activation of innate and adaptive (Th1 and Th17 mediated) immunity. Interleukin-6 (IL-6) plays an important role in the pathogenesis of CSS. The significant role of IL-6 in pathogenesis of COVID-19 was confirmed in a range of studies, which showed that the plasma concentration of IL-6 was increased in patients with severe COVID-19. Currently, IL-6 inhibitor therapeutics are not yet approved for the treatment of COVID-19; however, these medicines, including tocilizumab (TCZ) are used off-label for the treatment of patients with severe COVID-19, including life-threatening conditions. The role of IL-6 in the pathogenesis of CSS during COVID-19 is important however, a number of related issues are not yet clear. These issues include the indications for treatment with IL-6 inhibitors, as well as the estimation of risk associated with the disease, outcomes, treatment options, and adverse drug reactions. The development of personalized immunomodulatory therapy, with respect to the role of cytokines in pathogenesis, requires the studies that aimed to find other relevant therapeutic targets for the treatment of CSS in patients with COVID-19. These therapeutic targets include inhibition of IL-1, IL-6, TNFα, GM-CSF, IFNγ, IL-17, IL-18, and also activation of the complement system.

The challenge of CSS in patients with COVID-19 is identifying the correct scientific targets and developing clinical trials aimed to evaluate the pathogenesis and treat immune-mediated inflammatory diseases (IMIDs). Hopefully, the significant efforts of scientists and physicians across the globe will improve the prognosis in COVID-19 patients and provide useful information on IMIDs required to support the struggle for treating potential viral outbreaks, and treatment of well-known IMIDs.

El texto completo de este artículo está disponible en PDF.

Keywords : COVID-19, interleukin 6, cytokine storm syndrome


Esquema


© 2020  The Author(s). Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 131

Artículo 110698- novembre 2020 Regresar al número
Artículo precedente Artículo precedente
  • Stem cells in natural product and medicinal plant drug discovery—An overview of new screening approaches
  • Erastus Nembu Nembo, Jürgen Hescheler, Filomain Nguemo
| Artículo siguiente Artículo siguiente
  • The emerging role of lncRNAs in chondrocytes from osteoarthritis patients
  • Jiajie Tu, Wei Huang, Weiwei Zhang, Jiawei Mei, Chen Zhu

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.